AlphaStocks
6.2
Consider Buy

Haemonetics Corp (HAE)

As of Sep 20, 2026, Haemonetics Corp (HAE) scores 6.2/10 on AlphaStocks' five-model composite, #46 of 168 Health Care stocks. At $108, HAE trades 30% above its model fair value of $83.

Health Care / Health Care Supplies

S&P MidCap 400

$108.38

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#46out of 168 in Health Care

Is HAEMONETICS CORP a Good Investment in 2026?

HAEMONETICS CORP (HAE) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates HAEMONETICS CORP as Attractive (6/9). However, the Graham model rates it Caution — Significantly above fair value. HAEMONETICS CORP currently trades 30% above its estimated fair value of $83. HAEMONETICS CORP ranks #46 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E52.7ROE11.4Market Cap5B

Estimated Fair Value

$83.4830% above

Trading above estimated fair value. P/e of 53x implies high growth expectations. eps growth of -38% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Earnings yield 4.0% · ROC 22%

Frequently Asked Questions

Is HAEMONETICS CORP (HAE) a good investment?
As of Sep 20, 2026, Haemonetics Corp (HAE) scores 6.2/10 on AlphaStocks' five-model composite, #46 of 168 Health Care stocks. At $108, HAE trades 30% above its model fair value of $83. That is a middle-of-the-pack score with no strong signal either way.
What is HAEMONETICS CORP's Piotroski F-Score?
HAEMONETICS CORP's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is HAE overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $83, HAE appears overvalued. The stock currently trades 30% above its estimated fair value. Trading above estimated fair value. P/e of 53x implies high growth expectations. eps growth of -38% may not justify the premium.
How does HAE compare to other Health Care stocks?
HAEMONETICS CORP ranks #46 out of 168 stocks in the Health Care sector, placing it in the top 27% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about HAE?
AlphaStocks evaluates HAE using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 6.2/10.

Similar Stocks

WSTLNTHMMSI

Compare HAE with

HAE vs WSTHAE vs LNTHHAE vs MMSIHAE vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer